Home Tags ESMO 2019

Tag: ESMO 2019

ESMO 2019: Iksuda Therapeutics’ IKS01 Demonstrates Effective Tumor Regression

Peter Hofland
The first available data on Iksuda Therapeutics' (previously Glythera) lead antibody-drug conjugate, IKS01, has shown significant and effective tumor regression in preclinical models of...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

Phase I/IIa Trial Evaluating BT1718 Shows Encouraging Progress in Dose Escalation...

Danielle Garcia
Updated data from a Phase I/IIa trial evaluating BT1718, a Bicycle Toxin Conjugate being developed Bicycle Therapeutics, was presented during a poster session (Abstract...
ADC Review, Journal of Antibody-drug Conjugates
MADE POSSIBLE BY:
ADCBIO
Lonza
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policy makers.

Latest

Peer Review

© 2013-2019 Sunvalley Communication, LLC. All Rights Reserved.